Compare Biogen Inc (BIIB) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs iShares Semiconductor ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while iShares Semiconductor ETF trades at $548.47. The key difference: Biogen Inc is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | SOXX | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.63 | $655.01 |
52-Week Low | $132.22 | $241.68 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
SOXX trades at $546.61, up 3.12% on the day, with a bullish technical signal from moving averages and neutral oscillators. Support lies near $530 and resistance at $548. Recent news highlights sector volatility, including a 21% drop in July 2026 due to headwinds like short-seller commentary and competitive pressures, though cloud company growth supports AI spending optimism.
The outlook is mixed: strong AI demand from cloud providers offers upside, but concentration risk and tariff uncertainties pose threats. Investors face volatility from sector rotations and geopolitical factors, requiring careful risk assessment amid evolving semiconductor dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
